HC Wainwright Issues Negative Outlook for XENE Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Analysts at HC Wainwright lowered their Q3 2025 earnings per share (EPS) estimates for shares of Xenon Pharmaceuticals in a research report issued to clients and investors on Tuesday, August 12th. HC Wainwright analyst D. Tsao now expects that the biopharmaceutical company will post earnings per share of ($1.26) for the quarter, down from their previous forecast of ($1.25). HC Wainwright currently has a “Buy” rating and a $53.00 price target on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. HC Wainwright also issued estimates for Xenon Pharmaceuticals’ Q4 2025 earnings at ($1.33) EPS, FY2025 earnings at ($4.49) EPS, Q1 2026 earnings at ($1.33) EPS, Q3 2026 earnings at ($1.31) EPS, Q4 2026 earnings at ($1.43) EPS, FY2026 earnings at ($5.40) EPS, FY2027 earnings at ($5.98) EPS, FY2028 earnings at ($5.28) EPS and FY2029 earnings at ($3.79) EPS.

Other research analysts also recently issued reports about the company. Chardan Capital reaffirmed a “buy” rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday. Evercore ISI started coverage on Xenon Pharmaceuticals in a report on Wednesday, May 14th. They set an “outperform” rating and a $55.00 target price on the stock. Needham & Company LLC cut their target price on Xenon Pharmaceuticals from $60.00 to $55.00 and set a “buy” rating on the stock in a report on Tuesday, May 13th. The Goldman Sachs Group cut their target price on Xenon Pharmaceuticals from $60.00 to $52.00 and set a “buy” rating on the stock in a report on Thursday, April 17th. Finally, Wedbush lifted their target price on Xenon Pharmaceuticals from $42.00 to $43.00 and gave the stock an “outperform” rating in a report on Tuesday. One analyst has rated the stock with a sell rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $53.20.

Xenon Pharmaceuticals Trading Up 0.8%

Shares of XENE opened at $37.96 on Thursday. The company has a market capitalization of $2.93 billion, a PE ratio of -10.69 and a beta of 1.16. Xenon Pharmaceuticals has a 12 month low of $26.74 and a 12 month high of $46.00. The stock’s 50-day moving average price is $32.46 and its two-hundred day moving average price is $34.07.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Monday, August 11th. The biopharmaceutical company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($1.03) by ($0.04). During the same period in the previous year, the business earned ($0.75) earnings per share.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. GF Fund Management CO. LTD. increased its position in Xenon Pharmaceuticals by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 1,952 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 351 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Xenon Pharmaceuticals by 15.7% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,964 shares of the biopharmaceutical company’s stock valued at $93,000 after buying an additional 403 shares in the last quarter. Natixis Advisors LLC increased its position in Xenon Pharmaceuticals by 1.9% in the 1st quarter. Natixis Advisors LLC now owns 24,010 shares of the biopharmaceutical company’s stock valued at $806,000 after buying an additional 456 shares in the last quarter. Occudo Quantitative Strategies LP increased its position in Xenon Pharmaceuticals by 5.8% in the 4th quarter. Occudo Quantitative Strategies LP now owns 11,441 shares of the biopharmaceutical company’s stock valued at $448,000 after buying an additional 630 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Xenon Pharmaceuticals by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 69,529 shares of the biopharmaceutical company’s stock valued at $2,726,000 after buying an additional 720 shares in the last quarter. 95.45% of the stock is owned by institutional investors.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.